Company: AGIO
Filing Date: 2025-02-13
Form Type: 10-K
Source: 0001439222-25-000009
Chunk: 475

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-02-13
Form: 10-K
Item: Item 8
Chunk 475
---
Milestone revenue— — 2,500 Total revenue36,498 26,823 14,240 Operating expensesCost of sales$4,165 $2,881 $1,704 Research and development301,286 295,526 279,910 Selling, general and administrative156,784 119,903 121,673 Total operating expenses462,235 418,310 403,287 Loss from operations(425,737)(391,487)(389,047)Gain on sale of contingent payments889,136 — 127,853 Milestone payment from gain on sale of oncology business200,000 — — Royalty income from gain on sale of oncology business— — 9,851 Interest income, net48,083 33,344 12,793 Other income, net6,487 6,055 6,749 Net income (loss) before taxes717,969 (352,088)(231,801)Income tax expense44,244 — — Net income (loss)$673,725 $(352,088)$(231,801)Net income (loss) per share - basic$11.86 $(6.33)$(4.23)Net income (loss) per share - diluted$11.64 $(6.33)$(4.23)Weighted-average number of common shares used in computing net income (loss) per share – basic56,807,415 55,651,487 54,789,435 Weighted-average number of common shares used in computing net income (loss) per share – diluted57,889,255 55,651,487 54,789,435 

 See accompanying Notes to Consolidated Financial Statements.

F-5

Agios Pharmaceuticals, Inc.

Consolidated Statements of Comprehensive Income (Loss)

 (In thousands) Years Ended December 31:202420232022Net income (loss)$673,725 $(352,088)$(231,801)Other comprehensive (loss) incomeUnrealized (loss) gain on available-for-sale securities(1,077)12,094 (11,337)Comprehensive income (loss)$672,648 $(339,994)$(243,138)

See accompanying Notes to Consolidated Financial Statements.

F-6

Agios Pharmaceuticals, Inc.

Consolidated Statements of Stockholders’ Equity